2023-2027 World Tumor Marker Testing Market-High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers-A 92-Country Analysis-Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Major Tumor Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers
This new 92-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.The report is available by section, and can be customized to specific information needs and budget.
This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.
The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.
Rationale
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
Geographic Regions
Asia-Pacific, Europe, Latin America, Middle East, North America
Country Analyses
Albania, Argentina, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Egypt, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, Morocco, Myanmar, Netherlands, New Zealand, Nicaragua, Nigeria, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, UK, Ukraine, United Arab Emirates, Uruguay, USA, Venezuela, Vietnam
Business Opportunities and Strategic Recommendations
Introduction
Market Overview
Major Product Development Opportunities
Design Criteria for New Products
Alternative Market Penetration Strategies
Potential Market Entry Barriers and Risks
Major Current and Emerging Diagnostic Tests
Instrumentation Review and Market Needs
Current and Emerging Technologies
Market Size, Supplier Shares, Test Volume and Sales Segment Forecasts
Competitive Profiles and Strategies
This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.
The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.
Rationale
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
Geographic Regions
Asia-Pacific, Europe, Latin America, Middle East, North America
Country Analyses
Albania, Argentina, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Egypt, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, Morocco, Myanmar, Netherlands, New Zealand, Nicaragua, Nigeria, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, UK, Ukraine, United Arab Emirates, Uruguay, USA, Venezuela, Vietnam
Business Opportunities and Strategic Recommendations
- Specific new product development opportunities with potentially significant market appeal during the next five years.
- Design criteria for new products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
- Oncogenes %li%Biochemical Markers %li%Growth Factors %li%Colony Stimulating Factors %li%Hormones %li%Immunohistochemical Stains %li%Lymphokines
- ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.
- Sales and market shares of major cancer diagnostic product suppliers in major countries by individual test.
- Five-year test volume and sales forecasts for major cancer diagnostic assays.
- Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.
- Assessment of latest technologies and their potential applications for cancer diagnostic testing.
- Review of competing/complementing technologies.
- Companies, universities and research centers developing new cancer diagnostic tests and detection technologies.
- Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.
- The companies analyzed in the report include:
Introduction
Market Overview
Major Product Development Opportunities
Design Criteria for New Products
Alternative Market Penetration Strategies
Potential Market Entry Barriers and Risks
Major Current and Emerging Diagnostic Tests
Instrumentation Review and Market Needs
Current and Emerging Technologies
Market Size, Supplier Shares, Test Volume and Sales Segment Forecasts
Competitive Profiles and Strategies
I. INTRODUCTION
II. WORLDWIDE MARKET OVERVIEW
III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
V. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW
A. Cancer Statistics and Etiology
1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current and Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
27. Oncogenes
: :Abl/abl-bcr
: :AIB1
: :BCL-2
: :BRCA1
: :CD44
: :C-fos
: :C-myb
: :C-myc
: :CYP-17
: :Erb-B
: :HPC1
: :N-myc
: :P40
: :P51
: :P53
: :PIK3CA
: :PTI-1
: :Ras
: :Reg
: :Sis
: :Src and others
28. Polypeptide Growth Factors
: :Basic Fibroblast Growth Factor
: :Beta-TGF
: :Cachectin (TNT)
: :Calmodulin
: :ECFR
: :Nerve Growth Factor (NGF)
: :Epidermal Growth Factor (EGF)
: :Ornithine Decarboxylase
: :Transferrin
: :Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
: :Alpha-Interferon
: :B Cell Growth Factors
: :B Cell Growth Factor (BCGF)
: :Gamma-Interferon
: :Interleukin-1 (IL-1)
: :Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
: :N-Acetylglucosamine
: :Actin
: :Alpha-Actin
: :Antineuronal Antibodies
: :7B2
: :B72.3
: :Bax
: :BCD-F9
: :BLCA-4
: :Blood Group Antigens A,B,H
: :CA
: :CA 72-4/TAG-72
: :CA
: :CA-242
: :CA-549
: :CAM
: :CAR-3
: :Cathepsin-D
: :Chromogranin A and B
: :Cluster 1 Antigen
: :Cluster-5/5A Antigen
: :CTA
: :CU18
: :DR-70
: :DU-PAN-2
: :Endometrial Bleeding Associated Factor
: :Endostatin
: :Epithelial Membrane Antigen
: :Feulgen Hydrolysis
: :Fibronectin
: :FSH
: :(1-$$$$3)-L-fucosyltransferase
: :Gastrin-Releasing Peptide (GRP)
: :GDCFP-15
: :Glucagon
: :Glycoamines
: :H23
: :Her-2
: :Human Carcinoma Antigen
: :HPA
: :HSP27
: :Intermediate Filaments
: :Cytokeratins/CK18/Cyfra 21-1
: :Desmin
: :Gliofibrillary Acid Protein
: :Neurofilaments
: :Vimentin
: :KA
: :Kinases
: :KP16D3
: :LAI
: :Leukocyte Common Antigen
: :Lewis Antigens
: :Lysophosphatidic Acid (LPA)
: :Ma 695/Ma
: :MABDF3
: :MAG
: :ME1
: :Minactivin
: :MN/CA9
: :MSA
: :Mucin Cancer Antigen (MCA)
: :Multiple Tumor Suppressor
: :Myosin
: :NEA-130
: :NMP22
: :OA-519
: :Opioid Peptides
: :P-glycoprotein
: :Pancreatic Oncofetal Antigen (POA)
: :Placental Lactogen
: :PR92
: :Proliferative Index, Ki-67
: :Px
: :RB Inactivation/Deletion
: :Ret
: :SCCL
: :Selectin
: :Sialic Acid
: :Sialyl SSEA-1/SLX
: :SN10
: :Somatostatin
: :TA-90
: :TABA
: :Tachykinin
: :TAG
: :TPS
: :Troponin
: :Tubulin
: :VCAM
: :VEGF
: :Villen and others
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
E. Personal Testing
VIII. COUNTRY MARKET ANALYSES: CANCER DIAGNOSTICS MARKET TEST
Volume and Sales Forecasts for 97 Countries:
Albania, Algeria, Argentina, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Brazil,
Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic,
Denmark, Dominican Republic, Ecuador, Egypt, El Salvador, Estonia, Finland, France, Georgia,
Germany, Ghana, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, India,
Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kuwait, Latvia,
Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, Morocco, Myanmar, Netherlands, New
Zealand, Nicaragua, Nigeria, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland,
Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic,
Slovenia, South Korea, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, UK,
Ukraine, United Arab Emirates, Uruguay, USA, Venezuela, Vietnam
IX. COMPETITIVE PROFILES
The report provides strategic assessments of over 30 leading cancer diagnostics market players
and start-up companies with innovative technologies and products, including:
: :Abbott
: :Affymetrix
: :Beckman Coulter/Danaher/Cepheid
: :Becton Dickinson
: :bioMerieux
: :Bio-Rad
: :DiaSorin
: :Eiken Chemical
: :Elitech Group
: :Enzo Biochem
: :Fujifilm Wako
: :Fujirebio
: :Grifols
: :Hologic/Gen-Probe
: :Leica Biosystems/Kreatech
: :Qiagen
: :QuidelOrtho
: :Roche
: :Siemens Healthineers
: :Takara Bio
: :Thermo Fisher and others.
II. WORLDWIDE MARKET OVERVIEW
III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
V. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW
A. Cancer Statistics and Etiology
1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current and Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
27. Oncogenes
: :Abl/abl-bcr
: :AIB1
: :BCL-2
: :BRCA1
: :CD44
: :C-fos
: :C-myb
: :C-myc
: :CYP-17
: :Erb-B
: :HPC1
: :N-myc
: :P40
: :P51
: :P53
: :PIK3CA
: :PTI-1
: :Ras
: :Reg
: :Sis
: :Src and others
28. Polypeptide Growth Factors
: :Basic Fibroblast Growth Factor
: :Beta-TGF
: :Cachectin (TNT)
: :Calmodulin
: :ECFR
: :Nerve Growth Factor (NGF)
: :Epidermal Growth Factor (EGF)
: :Ornithine Decarboxylase
: :Transferrin
: :Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
: :Alpha-Interferon
: :B Cell Growth Factors
: :B Cell Growth Factor (BCGF)
: :Gamma-Interferon
: :Interleukin-1 (IL-1)
: :Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
: :N-Acetylglucosamine
: :Actin
: :Alpha-Actin
: :Antineuronal Antibodies
: :7B2
: :B72.3
: :Bax
: :BCD-F9
: :BLCA-4
: :Blood Group Antigens A,B,H
: :CA
: :CA 72-4/TAG-72
: :CA
: :CA-242
: :CA-549
: :CAM
: :CAR-3
: :Cathepsin-D
: :Chromogranin A and B
: :Cluster 1 Antigen
: :Cluster-5/5A Antigen
: :CTA
: :CU18
: :DR-70
: :DU-PAN-2
: :Endometrial Bleeding Associated Factor
: :Endostatin
: :Epithelial Membrane Antigen
: :Feulgen Hydrolysis
: :Fibronectin
: :FSH
: :(1-$$$$3)-L-fucosyltransferase
: :Gastrin-Releasing Peptide (GRP)
: :GDCFP-15
: :Glucagon
: :Glycoamines
: :H23
: :Her-2
: :Human Carcinoma Antigen
: :HPA
: :HSP27
: :Intermediate Filaments
: :Cytokeratins/CK18/Cyfra 21-1
: :Desmin
: :Gliofibrillary Acid Protein
: :Neurofilaments
: :Vimentin
: :KA
: :Kinases
: :KP16D3
: :LAI
: :Leukocyte Common Antigen
: :Lewis Antigens
: :Lysophosphatidic Acid (LPA)
: :Ma 695/Ma
: :MABDF3
: :MAG
: :ME1
: :Minactivin
: :MN/CA9
: :MSA
: :Mucin Cancer Antigen (MCA)
: :Multiple Tumor Suppressor
: :Myosin
: :NEA-130
: :NMP22
: :OA-519
: :Opioid Peptides
: :P-glycoprotein
: :Pancreatic Oncofetal Antigen (POA)
: :Placental Lactogen
: :PR92
: :Proliferative Index, Ki-67
: :Px
: :RB Inactivation/Deletion
: :Ret
: :SCCL
: :Selectin
: :Sialic Acid
: :Sialyl SSEA-1/SLX
: :SN10
: :Somatostatin
: :TA-90
: :TABA
: :Tachykinin
: :TAG
: :TPS
: :Troponin
: :Tubulin
: :VCAM
: :VEGF
: :Villen and others
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
E. Personal Testing
VIII. COUNTRY MARKET ANALYSES: CANCER DIAGNOSTICS MARKET TEST
Volume and Sales Forecasts for 97 Countries:
Albania, Algeria, Argentina, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Brazil,
Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic,
Denmark, Dominican Republic, Ecuador, Egypt, El Salvador, Estonia, Finland, France, Georgia,
Germany, Ghana, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, India,
Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kuwait, Latvia,
Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, Morocco, Myanmar, Netherlands, New
Zealand, Nicaragua, Nigeria, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland,
Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic,
Slovenia, South Korea, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, UK,
Ukraine, United Arab Emirates, Uruguay, USA, Venezuela, Vietnam
IX. COMPETITIVE PROFILES
The report provides strategic assessments of over 30 leading cancer diagnostics market players
and start-up companies with innovative technologies and products, including:
: :Abbott
: :Affymetrix
: :Beckman Coulter/Danaher/Cepheid
: :Becton Dickinson
: :bioMerieux
: :Bio-Rad
: :DiaSorin
: :Eiken Chemical
: :Elitech Group
: :Enzo Biochem
: :Fujifilm Wako
: :Fujirebio
: :Grifols
: :Hologic/Gen-Probe
: :Leica Biosystems/Kreatech
: :Qiagen
: :QuidelOrtho
: :Roche
: :Siemens Healthineers
: :Takara Bio
: :Thermo Fisher and others.
